Replimune stock.

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ...At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Replimune Group Stock Performance. Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 12.76 and a quick ratio of 12.76.

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize …We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.Nov 8, 2023 · WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.

Nov 28, 2023 · Replimune Group stock was originally listed at a price of $15.16 in Jul 20, 2018. If you had invested in Replimune Group stock at $15.16, your return over the last 5 years would have been 4.88%, for an annualized return of 0.96% (not including any dividends or dividend reinvestments). Replimune Group Stock Price | REPL Stock Quote, News, and History | Markets Insider The latest Replimune Group stock prices, stock quotes, news, and …

Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'10.39 +0.10 (0.97%) At close: Nov 24, 2023, 1:00 PM 10.86 +0.46 (4.48%) After-hours: Nov 24, 2023, 1:26 PM EST Financials No 1Y chart data available About …

Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...

Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Replimune Group stock price forecast: $52; Market Cap: 686.26M, Enterprise value: 781.76M, P/E: -5.9, PEG ratio: 0.20, EPS: -3.1, Revenue: N/A, ...Oct 15, 2020 · Replimune (NASDAQ: REPL) stock price soared sharply to an all-time high of $46 in Wednesday trading before settling around $36 a share at the end of the session. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POST

Replimune Group Stock Performance Shares of REPL stock opened at $11.71 on Monday. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.Replimune Group, Inc. announced that members from the Replimune management team ... shares of its common stock at a public offering price of $23.50 per share.Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Replimune story: Amylyx snatched the landmark approval for its ALS drug. Now its seeking cash to foot the launch bill - Endpoints News and other headlines for Replimune Group Please click here if you are not redirected within a few seconds.Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued. WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed ...

Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...Dec 1, 2023 · Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively ... Founded Date Mar 2015. Founders Philip Sparke, Robert Coffin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Replimune Group Inc. Stock Symbol NASDAQ:REPL. Company Type For Profit. Contact Email [email protected]. Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the …Shares of Replimune have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. ... The stock could also be impacted by negative ...Why Replimune Stock Is Soaring Today. 485%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 485% . S&P 500 Returns. 126%.Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ...Report of unscheduled material events or corporate event. 8-K. 0001104659-23-115027.pdf. 0001104659-23-115027.rtf. 0001104659-23-115027.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 07, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q.

Novartis AG. -0.52%. CHF176.38B. REPL | Complete Replimune Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.

He joins Ankyra from Replimune, where he served as the chief accounting officer and was responsible for financial, accounting, tax and human resources functions, and played a key role in the company’s successful 2018 initial public offering. Before Replimune, he served as vice president, finance and administration at uniQure. ...Nov 28, 2023 · Stock analysis for Replimune Group Inc (REPL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...They pay benefits on behalf of the employees. Healthcare and life insurance without premiums. Good benefits, could use HSA. Great benefits, growing company, plenty to learn. Free health care is very good. Good stock options, and retirement matching.Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...Exhibit 10.4 . REPLIMUNE GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN . I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Replimune Group, Inc., a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through …Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.

Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ...WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023.Exhibit 10.4 . REPLIMUNE GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN . I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Replimune Group, Inc., a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through …Instagram:https://instagram. no annual maximum dental insurancemicrosoft goes publicmaxeon stockhow does equitybee work Item 1. Description of Registrant’s Securities to be Registered. A description of the common stock of Replimune Group, Inc. (the “Registrant”), par value $0.001 per share, to be registered hereunder is set forth under the caption “Description of capital stock” in the prospectus that constitutes a part of the Registrant’s Registration Statement on Form S … vanguard high dividend yield etf dividend historyallstate motorcycle insurance Today's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max | ftabx Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ... See Insiders’ Hot Stocks on TipRanks >> Replimune Group (REPL) Barclays analyst Peter Lawson assigned a Buy rating to Replimune Group yesterday and set a price target of $50.00.The company’s ...